Syndax Pharmaceuticals Reports Fourth Quarter and Year-end 2016 Financial Results and Provides Clinical and Business Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. META
4. ABBV
5. FDX
6. IBM
7. MU
8. PFE
9. ACN
10. USO

Go back to Syndax Pharmaceuticals Reports Fourth Quarter and Year-end 2016 Financial Results and Provides Clinical and Business Update

UPDATE: Syndax Pharmaceuticals (SNDX) Tops Q4 EPS by 11c; Encore 601 Refractory Melanoma Cohort to Proceed to Second Stage of Phase 2

March 2, 2017 4:07 PM EST

(Updated - March 2, 2017 4:35 PM EST)

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q4 EPS of ($0.59), $0.11 better than the analyst estimate of ($0.70). Revenue for the quarter came in at $305 thousand versus the consensus estimate of $150 thousand.

"Were pleased to report that the melanoma cohort of ENCORE 601 has met the pre-specified objective response threshold... More